Evidence map›Paper›PMID 26269179›Full record

ArticleJournal of virology2015

Replication-Competent Controlled Herpes Simplex Virus.

David C Bloom, Joyce Feller, Peterjon McAnany, Nuria Vilaboa, Richard Voellmy

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

David C BloomDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, USA.
Joyce FellerDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, USA.
Peterjon McAnanyDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, USA.
Nuria VilaboaHospital Universitario La Paz, IdiPAZ, Madrid, Spain CIBER de Bioingenieria, Biomateriales y Nanomedicina, Barcelona, Spain.
Richard VoellmyHSF Pharmaceuticals SA, La Tour-de-Peilz, Switzerland Department of Physiological Sciences, University of Florida College of Veterinary Sciences, Gainesville, Florida, USA rvoellmy@hsfpharma.com.
Florida College · USBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledWe present the development and characterization of a replication-competent controlled herpes simplex virus 1 (HSV-1). Replication-essential ICP4 and ICP8 genes of HSV-1 wild-type strain 17syn+ were brought under the control of a dually responsive gene switch. The gene switch comprises (i) a transactivator that is activated by a narrow class of antiprogestins, including mifepristone and ulipristal, and whose expression is mediated by a promoter cassette that comprises an HSP70B promoter and a transactivator-responsive promoter and (ii) transactivator-responsive promoters that drive the ICP4 and ICP8 genes. Single-step growth experiments in different cell lines demonstrated that replication of the recombinant virus, HSV-GS3, is strictly dependent on an activating treatment consisting of administration of a supraphysiological heat dose in the presence of an antiprogestin. The replication-competent controlled virus replicates with an efficiency approaching that of the wild-type virus from which it was derived. Essentially no replication occurs in the absence of activating treatment or if HSV-GS3-infected cells are exposed only to heat or antiprogestin. These findings were corroborated by measurements of amounts of viral DNA and transcripts of the regulated ICP4 gene and the glycoprotein C (gC) late gene, which was not regulated. Similar findings were made in experiments with a mouse footpad infection model. IMPORTANCE: The alphaherpesviruses have long been considered vectors for recombinant vaccines and oncolytic therapies. The traditional approach uses vector backbones containing attenuating mutations that restrict replication to ensure safety. The shortcoming of this approach is that the attenuating mutations tend to limit both the immune presentation and oncolytic properties of these vectors. HSV-GS3 represents a novel type of vector that, when activated, replicates with the efficiency of a nonattenuated virus and whose safety is derived from deliberate, stringent regulation of multiple replication-essential genes. By directing activating heat to the region of virus administration, replication is strictly confined to infected cells within this region. The requirement for antiprogestin provides an additional level of safety, ensuring that virus replication cannot be triggered inadvertently. Replication-competent controlled vectors such as HSV-GS3 may have the potential to be superior to conventional attenuated HSV vaccine and oncolytic vectors without sacrificing safety.

Indexed as

Gene Expression Regulation, ViralAnimalsChlorocebus aethiopsDNA-Binding ProteinsDNA, ViralGenes, SwitchGenetic EngineeringGenetic VectorsHeLa CellsHerpes SimplexHerpesvirus 1, HumanHindlimbHot TemperatureHSP70 Heat-Shock ProteinsHumansImmediate-Early ProteinsDNA-Binding ProteinsDNA, Viralglycoprotein gC, herpes simplex virus type 1herpes simplex virus, type 1 protein ICP4HSP70 Heat-Shock ProteinsHSPA7 protein, humanICP8 protein, SimplexvirusImmediate-Early ProteinsMifepristoneNorpregnadienesRNA, MessengerulipristalViral Envelope ProteinsViral Proteins

Identifiers

PMID26269179
PMCPMC4580158
OpenAlexW1910466289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.